August 9, 2023 - CalciMedica Announces First Patient Enrolled in International Expansion of CARPO Trial of Auxora™ in Acute Pancreatitis (AP) Read More

June 27, 2023 - Chimerix Announces Promotion of Michael T. Andriole to President and Chief Executive Officer Read More

June 21, 2023 - Metavention’s Renal Denervation Pivotal IDE Study now Approved by FDA for the Treatment of Hypertension Read More

June 12, 2023 - CalciMedica Announces Relisting on Nasdaq Read More

May 31, 2023 - Association Between Mobilization and Composite Postoperative Complications Following Major Elective Surgery Read More

March 20, 2023 - CalciMedica Announces Closing of Merger with Graybug Vision and Concurrent Private Placement Read More

January 9, 2023 - Glycomine Announces First Patient Dosed in Phase 2 Clinical Study of GLM101, a Potential Treatment for PMM2-CDG Read More

July 11, 2022 - Vertex to Acquire ViaCyte, With the Goal of Accelerating its Potentially Curative VX-880 Programs in Type 1 Diabetes Read More

July 11, 2022 - Glycomine Appoints Steven Axon as CEO and Adds Two New Board Directors Read More

February 2, 2022 - CRISPR Therapeutics and ViaCyte, Inc. Announce First Patient Dosed in Phase 1 Clinical Trial of Novel Gene-Edited Cell Replacement Therapy for Treatment of Type 1 Diabetes (T1D) Read More